GlassScriptPhysician profile
Kevin S Skole
NPI 1568431914
$15,930.44
in general payments reported to CMS, 2019-2025
34 companies · $2,714 in 2025
The $2,714 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $350 · 2021: $444 · 2022: $726 · 2023: $5,572 · 2024: $5,708 · 2025: $2,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $3,332 · Education: $36.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,625.00 |
| Food and Beverage | $3,332.10 |
| Education | $36.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $4,747.52 | 2022-2023 | Rebyota |
| Pfizer INC. | $3,357.72 | 2019-2025 | |
| Exact Sciences Corporation | $3,034.83 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $1,749.64 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $573.47 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $445.68 | 2020-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.69 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $377.74 | 2024-2025 | Voquezna |
| Genzyme Corporation | $233.79 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $134.23 | 2023-2025 | Ocaliva |
| Celgene Corporation | $116.59 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $106.75 | 2019-2024 | Linzess |
| Lilly USA, LLC | $56.72 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $52.75 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $50.71 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $50.00 | 2023 | |
| Aimmune Therapeutics, INC. | $48.12 | 2023-2025 | Vowst |
| Allergan, INC. | $47.68 | 2019 | |
| Ardelyx, INC. | $41.53 | 2025 | Ibsrela |
| Laborie Medical Technologies Corp. | $40.41 | 2024 | |
| Nestle Healthcare Nutrition INC. | $32.79 | 2022-2023 | |
| Coloplast Corp | $32.58 | 2019 | |
| Shionogi INC | $29.24 | 2019 | |
| Echosens North America, INC. | $26.03 | 2023 | Fibroscan |
| Fresenius Kabi USA, LLC | $19.87 | 2023 | Idacio |
| Pharmacosmos Therapeutics INC. | $18.69 | 2025 | Monoferric |
| Merck Sharp & Dohme LLC | $18.69 | 2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $18.49 | 2024 | Bylvay |
| Dynavax Technologies Corporation | $15.49 | 2025 | Heplisav-B |
| Ethicon US, LLC | $15.35 | 2019 | |
| Daiichi Sankyo INC. | $14.53 | 2019 | |
| Agile Therapeutics, INC. | $14.46 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.57 | 2024 | Givlaari |
| Novo Nordisk INC | $13.09 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Skole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.